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INTRODUCTION
In the past decade, the field of genomics has rapidly changed and expanded.1 With
these advancements also come new applications of genomics and genetics to clinical
medicine. The information gathered from genetic testing and genome sequencing can
reveal a great deal about not only an individual’s current health, but his/her future
health as well.2 This rapid expansion of scientific and medical capacity is accompanied
by rapid changes for law and policy making thoughtful regulation essential.
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See generally, Asude Alpman Durmaz et al., Evolution of Genetic Techniques: Past, Present, and Beyond, 2105
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Genetic Testing, GENETIC HOME REFERENCE, Sept. 7, 2015, http://ghr.nlm.nih.gov/handbook/testing?show=
all#interpretingresults (accessed Sept. 13, 2015).
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A problem not yet manifest: gaps in
insurance coverage of medical
interventions after genetic testing
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IMPACT OF THE ACA
The ACA sought to increase the number of individuals in the U.S.A. with adequate
health insurance by creating employer and individual mandates, creating new mechanisms for affordable coverage (health care exchanges), and expanding eligibility for
insurance under existing mechanisms (primarily Medicaid). In addition to covering
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Robert C. Green et al., ACMG Recommendations for Reporting Incidental Findings in Clinical Exome and Genome
Sequencing, 15 GENET. MED. 4 (2013).
Id. at 570.
Id. at 577.
Anya E.R. Prince, Prevention for Those Who Can Pay: Insurance Reimbursement of Genetic-based Preventive Interventions in the Liminal State between Health and Disease, 2 J. L. BIOSCI. 365–395 (2015).
Jessica C. Smith & Carla Medalia, Health Insurance Coverage in the United States: 2013, U.S. DEP’T. COM.,
Sept. 2014, https://www.census.gov/content/dam/Census/library/publications/2014/demo/p60–250.pdf
(accessed Sept. 14, 2015).
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The human genome includes many variations, most of which have no known significance. However, some variants can be the cause of important medical conditions,
and for a subset of these, there are useful healthcare interventions, which can be deployed if the genetic variation is recognized. Sometimes, these genetic variations are
the specific target of a genetic test. Sometimes, the variations are found incidentally,
in a genetic test performed for other purposes, such as pharmacogenomics or preconception screening.3 In 2013, the American College of Genetic Medicine (ACMG)
released recommendations specifying which of these incidental findings should be
given to clinicians.4 The ACMG limited its recommendation to 56 genetic variations, which can result in approximately 24 genetic conditions. Most of these genetic
conditions are very rare, with many of the available treatments limited to continued
monitoring and increased surveillance for changes in symptomology and/or disease
progression.5
Anya E.R. Prince discusses these issues in her article, ‘Prevention for those who can
pay: insurance reimbursement of genetic-based preventive interventions in the liminal state between health and disease.’6 Prince worries that while many health insurance
companies offer coverage for genetic testing, fewer offer coverage for prophylactic measures and treatments for the conditions said testing might reveal.
Lack of such coverage would undermine the policy goals that motivated insurance coverage mandates in the first place, and may perpetuate health disparities. We advance Prince’s analysis of this issue by exploring actual coverage in
the private health insurance market, which covers 64 per cent of Americans.7 In
particular, we analyse the coverage of two genetic conditions—BRCA and catecholaminergic polymorphic ventricular tachycardia (CPVT)—by reviewing policy documents of commercial health insurance companies, including Cigna, Aetna,
Blue Cross Blue Shield, and United Health One. We find that, while genetic testing and consequent treatment is not universally covered, many companies do offer a broad scope of coverage in this area. Prince argues that the Affordable Care
Act (ACA) and ACMG tout preventative measures without considering the impact
the information can have on individuals who are unable to afford the preventative
next steps.
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INSUR ANCE COVER AGE
There are multiple ways in which a genetic test or subsequent treatment may not be
subject to a legal coverage mandate. The plan may be grandfathered, and thus not
subject to ACA coverage mandate. Or, the tests may not be recommended by the
USPSTF. On the other hand, there are market forces, which shape private health insurance coverage, as well as more general legal principles, such as the contractual requirement for an insurer to cover medically necessary healthcare. Accordingly, we sought to
understand whether the coverage gaps hypothesized by Prince actually exist in the real
world of health insurance. To test this question, we selected two genetic conditions,
which are medically actionable: BRCA and CPVT.13 The UPSTF has recommended
BRCA testing for women with family histories, but it has not made a genetic screening
recommendation with regard to CPVT.14
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Preventive Services Covered under the Affordable Care Act, HHS. gov, U.S. DEP’T HEALTH HUM. SERV,
Sept. 27, 2012 [hereinafter Preventive Services], http://www.hhs.gov/healthcare/facts/factsheets/2010/07/
preventive-services-list.html (accessed Sept. 13, 2015).
Affordable Care Act Implementation FAQs – Set 12, CMS. gov, CTR . FOR MEDICARE AND MEDICAID SERV.,
https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca implementation faqs12.html (accessed Sept. 13, 2015).
Id.
Coverage of Preventive Health Services, 29 C.F.R. § 2590.715 (2011).
See generally U.S. Preventive Services Task Force, Sept. 2014, http://www.uspreventiveservicestaskforce.org/
(accessed Sept. 13, 2015).
See Green, supra note 4, at 570 (listing both of these conditions).
See BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing, U.S. Preventative
Services Task Force, Dec. 2013, http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing (stating the recommendation); The Center for Consumer Information & Insurance Oversight, Centers for Medicare
and Medicaid Services: Affordable Care Act Implementation FAQs - Set 12, CMS.GOV, available at
https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca implementation faqs12.html (interpreting the UPSTF recommendation to apply to the testing itself).
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more people, the ACA tried to improve the quality of coverage, imposing caps on cost
sharing and mandatory benefit packages. Preventative services are a cornerstone of the
ACA, including immunizations, HIV screening, and well-woman visits.8
Section 2713 of the ACA requires non-grandfathered group plans as well as insurance offered in the individual or group market to provide coverage for evidence-based
services that received a rating of A or B from the United States Preventative Task Force
(USPSTF).9 The ACA instructs that when a recommendation applies to a high-risk
population, the recommended service must be covered for individuals within that population if deemed appropriate by a clinician.10 Section 2713 also states that additional
coverage for services beyond those provided by the USPSTF is not prohibited.11 These
provisions apply to those genetic tests and subsequent treatments that the USPSTF
deems both beneficial and substantially backed by available evidence.12 Thus, under
the ACA, coverage for certain genetic tests and treatments has increased, although not
all of the genetic conditions identified by the ACMG have received the requisite rating
of an A or B by the USPSTF to mandate coverage.
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BRCA1 and BRCA 2: Cancer Risk and Genetic Testing, NAT’L CANCER INST., Apr. 1, 2015 [hereinafter Cancer
Risk] http://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#q1 (accessed Sept.
13, 2015).
Id.
Id.
Id.
Id.
Prince, supra note 8, at 12.
Cancer Risk, supra note 16.
Prince, supra note 8, at 13.
Genetic Testing for Susceptibility to Breast and Ovarian Cancer (e.g. BRCA 1 & BRCA 2), CIGNA MEDICAL
COVERAGE POLICY 1–5, Aug. 15, 2015 [hereinafter Susceptibility to Breast and Ovarian Cancer],
https://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/medical/mm 0001 coverageposition
-criteria genetic testing for breast and ovarian cancer.pdf (accessed Sept. 13, 2015).
Id. at 7.
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BRCA
Made famous in recent years by the actress Angelina Jolie, BRCA1 and BRCA2 are
protein-producing genes that repair damaged DNA and help ensure the stability of a
cell’s genetic material, which, in turn, suppresses tumour growth.15 Variations in these
genes undermine the normal and necessary process of DNA repair, and hence, can
cause genetic alterations to cells and lead to cancer.16 Some of these variants to the
genes can be inherited and can increase the risk of both breast and ovarian cancers
in women.17 According to the National Cancer Institute, BRCA variants are responsible for approximately 20–25 per cent of hereditary breast cancers, 5–10 per cent of all
breast cancers, and about 15 per cent of ovarian cancers.18 Additionally, lifetime risk for
developing breast cancer is as high as 90 per cent if a woman inherits a harmful BRCA1
or BRCA2 variation.19
Prince writes that although variations to the BRCA1 and BRCA2 genes are one of
the more widely studied genetic conditions, insurance companies provide varying levels of coverage for both genetic testing and recommended interventions.20 These interventions include breast cancer screening beginning at an earlier age since cancers linked
to BRCA mutations often develop in women in their 20s and 30s as well as prophylactic
mastectomy and/or oophorectomy.21 Prince goes on to state that, ‘Insurance coverage
for genetic services following BRCA testing, such as genetic counseling, screening, and
prophylactic surgery, is even less of an assurance than insurance coverage for the genetic
test itself.’22
To explore this potential problem, we examined the actual medical coverage policies
of major private insurance companies. Cigna, for instance, offers BRCA1 and BRCA 2
genetic testing for individuals with a known familial mutation, personal history of breast
or other cancers, or a family history of breast, ovarian, or pancreatic cancer.23 Cigna
does ‘not’, however, cover BRCA1 or BRCA2 genetic testing in the general population,
in individuals with no personal history of breast or ovarian cancer, and individuals under
the age of 18.24 Similarly, United Healthcare’s policy states that BRCA1 and BRCA2
testing is medically necessary (ie, covered under standard contractual coverage provisions) for customers including, but not limited to women with a personal history of
breast cancer who were diagnosed at 45 or younger with or without a family history of
cancer; women with a personal history of breast cancer diagnosed at 50 or younger with
one close blood relative with breast cancer or unknown family history; women without
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Genetic Testing for Hereditary Breast and/or Ovarian Cancer Syndrome (HBOC), UNITED HEALTHCARE MEDICAL
POL’ Y 3, Dec. 1, 2014, https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/
Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/Policies%20and%20Protocols/Medical%20Policies/C&S/genetic testing for hereditary breast ovarian cancer syndrome hboc
CS.pdf (accessed Sept. 13, 2015).
See Id., supra note 15, at 1 (‘The USPSTF recommends that primary care providers screen women who have
family members with breast, ovarian, tubal, or peritoneal cancer with 1 of several screening tools designed to
identify a family history that may be associated with an increased risk for potentially harmful mutations in
breast cancer susceptibility genes (BRCA1 or BRCA2). Women with positive screening results should receive
genetic counseling and, if indicated after counseling, BRCA testing. The USPSTF recommends against routine
genetic counseling or BRCA testing for women whose family history is not associated with an increased risk
for potentially harmful mutations in the BRCA1 or BRCA2 genes.’).
Prince, supra note 8, at 13.
BRCA Testing, Prophylactic Mastectomy, and Prophylactic Oophorectomy, AETNA, July 21 [hereinafter BRCA
Testing], 2015, http://www.aetna.com/cpb/medical/data/200 299/0227.html (accessed Sept. 13, 2015).
Id.
Prophylactic Oophorectomy or Salpingo-oophorectomy With or Without Hysterectomy, CIGNA MEDICAL
COVERAGE POLICY, Feb. 15, 2015, https://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/
medical/mm 0026 coveragepositioncriteria prophylactic oopherectomy.pdf (accessed Sept. 13, 2015);
Prophylactic Mastectomy and Breast Reconstruction after Mastectomy, BLUE CROSS BLUE SHIELD OF MASS.,
Sept. 1, 2015, http://www.bluecrossma.com/common/en US/medical policies/459%20Prophylactic%
20Mastectomy%20and%20Breast%20Reconstruction%20after%20Mastectomy%20prn.pdf (accessed Sept.
13, 2015) (Note: Because Blue Cross Blue Shield coverage varies state to state not all plans offer coverage for
prophylactic mastectomies).
Prophylactic Oophorectomy or Salpingo-oophorectomy With or Without Hysterectomy, CIGNA MEDICAL
COVERAGE POLICY, Feb. 15, 2015, https://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/
medical/mm 0026 coveragepositioncriteria prophylactic oopherectomy.pdf (accessed Sept. 13, 2015); Prophylactic Mastectomy and Breast Reconstruction after Mastectomy, BLUE CROSS BLUE SHIELD OF MASS.,
Sept. 1, 2015, http://www.bluecrossma.com/common/en US/medical policies/459%20Prophylactic%20
Mastectomy%20and%20Breast%20Reconstruction%20after%20Mastectomy%20prn.pdf (accessed Sept. 13,
2015) (Note: Because Blue Cross Blue Shield coverage varies state to state not all plans offer coverage for
prophylactic mastectomies).
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a personal history of breast or ovarian cancer with a known BRCA1 or BRCA2 mutation
in the family; and, women with a personal history of ovarian cancer.25 Remarkably, the
coverage provided by these insurers is in some ways broader than that recommended
by USPSTF.26
Prince argues that, ‘Insurance coverage for genetic services following BRCA testing, such as genetic counseling, screening, and prophylactic surgery, is even less of an
assurance than insurance coverage for the genetic test itself.’27 Our review of policy
documents found that, not only do many of these companies offer coverage for screening, they also cover prophylactic mastectomies and oophorectomies for their clients.
Aetna’s policy, for example, states that it considers prophylactic mastectomy medically
necessary to reduce breast cancer in high-risk women including those with BRCA1 or
BRCA2 mutations that have been confirmed by molecular susceptibility testing.28 The
same policy covers prophylactic bilateral oophorectomy or salpingo-oophorectomy
for women with BRCA1 or BRCA2 mutations.29 Other major insurance companies
also cover prophylactic mastectomies and/or oophorectomies when it is considered
medically necessary for customers who have a high risk of breast cancer.30 In nearly
all of the policies looked at, definitions of high risk included a BRCA1 or BRCA2
mutation.31
These findings should not be surprising. Such policies represent sound financial
decisions for insurance companies, since ‘the strategy of prophylactic mastectomy
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and oophorectomy ha[s] the lowest overall cost’ for insurers—this is the least expensive method for managing the insured’s risk.32 This dynamic is unlike the economics behind much preventative care, which—contrary to much political rhetoric—
is not cost effective, from a financial point of view, given the inability to target only
that subset of individuals at the highest risk of developing a disease long into the
future.33
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See generally, Victor R. Grann et al., Comparative Effectiveness of Screening and Prevention Strategies Among
BRCA1/2-affected Mutation Carriers, 125 BREAST CANCER RES. TREAT. 844 (2011).
See generally, Joshua T. Cohen et al., Does Preventive Care Save Money? Health Economics and the Presidential
Candidates, 358 NEW ENG. J. MED. 661 (2008).
Catecholaminergic Polymorphic Ventricular Tachycardia, Genetics Home Reference, Dec. 2009, http://ghr.nlm.
nih.gov/condition/catecholaminergic-polymorphic-ventricular-tachycardia (accessed Sept. 13, 2015).
Id.
Id.
Id.
Genetic Testing, AETNA, May 6, 2015, http://www.aetna.com/cpb/medical/data/100 199/0140.html
(accessed Sept. 13, 2015).
Policy Update Bulletin, UNITED HEALTHCARE 4, June 2015, https://www.unitedhealthcareonline.com/
ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%
20Resources/Policies%20and%20Protocols/Medical%20Policies/SV%20MPUBs/MMG%20Update%20
Bulletin June%202015.pdf (accessed Sept. 13, 2015).
Wearable Cardioverter Defibrillator and Automatic External Defibrillator, CIGNA 3, Feb. 15, 2015,
https://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/medical/mm 0431 coverageposition
criteria wearable cardioverter defibrillator and aed.pdf (accessed Sept. 13, 2015).
Id. at 6.
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CPVT
CPVT causes arrhythmia, or abnormal heart rhythm, which can cause an overly fast
and irregular heartbeat.34 This abnormal heartbeat can lead to light-headedness, dizziness, fainting, and even death.35 According to estimates, the condition affects approximately 1 in 10,000 people and can result when variants in one of two genes—RYR2
and CASQ2—occur.36 The variants, which cause disruption to the handling of calcium
within the heart muscle cells (myocytes), are responsible for approximately 50 per cent
and 1–2 per cent of all cases, respectively.37
Aetna offers coverage of genetic testing for CPTV in children and young adults who
have a first degree relative with a diagnosis of CPTV as well as for individuals who
have structurally sound hearts but exhibit exercise and/or emotion induced PVT or
ventricular fibrillation.38 United Healthcare’s most recently released guidelines also
state that genetic tests for CPTV are medically necessary when certain criteria are
met.39
Following a positive genetic test, insurers do cover relevant interventions. For example, Cigna provides coverage for transvenous implantable cardioverter defibrillator
(ICD) for genetic conditions including CPTV when medically necessary.40 ICDs are
devices that are surgically implanted in order to continuously monitor the heart rate of
the user and deliver a shock whenever an arrhythmia is detected in order to stop the
arrhythmia.41 The devices, which reduce the risk of cardiac arrest, are useful in individuals who experience frequent arrhythmic events and are a beneficial therapy for people
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with CPTV.42 Like Cigna, Aetna also covers ICDs in individuals with familial or inherited CPTV who have ‘syncope and/or documented sustained VT while receiving
beta-blockers’.43

42
43
44

Id.
Cardioverter-Defibrillators, AETNA, Aug. 28, 2015, http://www.aetna.com/cpb/medical/data/500 599/
0585.html (accessed Sept. 13, 2015).
See eg Susceptibility to Breast and Ovarian Cancer, supra note 24; BRCA Testing, supra note 29.
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CAVE ATS AND CONCLUSIONS
We explored merely two medically actionable genetic conditions (BRCA and CPTV),
using a convenience sample of policy documents, available on the internet. We cannot
say whether the insurance coverage for these two genetic variations is representative
of the more than two dozen other medically actionable variations recommended by
ACMG.
We also searched for explicit screening and treatment for these two conditions in
policy guidance documents. Insurance policies are complex, lengthy documents with
many caveats and exemptions. The actual terms of the contract, including coverage of
‘medically necessary’ care, and certain exclusions, will govern. In particular, nearly every insurer precludes coverage for treatment that is deemed ‘experimental’, although it
is not always clear what constitutes experimental treatment or what degree of proof is
needed to warrant coverage.44 These prohibitions could block access to coverage for a
number of these conditions, where evidence supporting the efficacy and safety of treatment is lacking.
Nonetheless, when looking at the companies’ own policy guidance documents, we
were unable to document the problems that Prince hypothesized. We found that major insurers do cover not only a range of genetic tests but also treatment and surveillance for those conditions that can benefit from increased monitoring and proactive
treatment.
Thus, our preliminary review of the evidence for these particular insurers, in this
particular market, for these particular genetic variations, suggest that Prince’s worries about gaps in coverage may be more theoretical than real. Nonetheless, as the
science and medicine evolves, these ethical and legal issues should continue to be
monitored and resolved in order to ensure that barriers to needed healthcare do not
arise.

